{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T17:23:56Z","timestamp":1791393836884,"version":"4.3.3"},"reference-count":84,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2014,8,1]],"date-time":"2014-08-01T00:00:00Z","timestamp":1406851200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["ecco-jccjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Crohn's and Colitis"],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1016\/j.crohns.2014.02.025","type":"journal-article","created":{"date-parts":[[2014,4,16]],"date-time":"2014-04-16T12:45:13Z","timestamp":1397652313000},"page":"726-734","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":86,"title":["Future directions in inflammatory bowel disease management"],"prefix":"10.1093","volume":"8","author":[{"given":"Geert R.","family":"D'Haens","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Balfour","family":"Sartor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark S.","family":"Silverberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"Petersson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Rutgeerts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","reference":[{"key":"10.1016\/j.crohns.2014.02.025_bb0005","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.crohns.2012.09.002","article-title":"Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management","volume":"6","author":"Dignass","year":"2012","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.crohns.2014.02.025_bb0010","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.crohns.2009.12.002","article-title":"The second European evidence-based consensus on the diagnosis and management of Crohn's disease: current management","volume":"4","author":"Dignass","year":"2010","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.crohns.2014.02.025_bb0015","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1159\/000338137","article-title":"How to guide therapeutic decisions in a patient-tailored approach to treatment of IBD?","volume":"30","author":"Rutgeerts","year":"2012","journal-title":"Dig Dis"},{"key":"10.1016\/j.crohns.2014.02.025_bb0020","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1097\/MEG.0b013e32835414b2","article-title":"Mucosal healing restores normal health and quality of life in patients with inflammatory bowel disease","volume":"24","author":"Casellas","year":"2012","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.crohns.2014.02.025_bb0025","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1002\/ibd.20997","article-title":"Importance of mucosal healing in ulcerative colitis","volume":"16","author":"Lichtenstein","year":"2010","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.crohns.2014.02.025_bb0030","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1053\/j.gastro.2007.05.051","article-title":"Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort","volume":"133","author":"Froslie","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.crohns.2014.02.025_bb0035","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1002\/ibd.20927","article-title":"Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease","volume":"15","author":"Schnitzler","year":"2009","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.crohns.2014.02.025_bb0040","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1002\/ibd.22977","article-title":"Mucosal healing in Crohn's disease: a systematic review","volume":"19","author":"De Cruz","year":"2013","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.crohns.2014.02.025_bb0045","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1053\/j.gastro.2009.09.056","article-title":"Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease","volume":"138","author":"Baert","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.crohns.2014.02.025_bb0050","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/S0140-6736(08)60304-9","article-title":"Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial","volume":"371","author":"D'Haens","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.crohns.2014.02.025_bb0055","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.crohns.2012.05.015","article-title":"Subgroup analysis of the placebo-controlled CHARM trial: increased remission rates through 3years for adalimumab-treated patients with early Crohn's disease","volume":"7","author":"Schreiber","year":"2013","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.crohns.2014.02.025_bb0060","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1038\/ajg.2010.78","article-title":"Increased response and remission rates in short-duration Crohn's disease with subcutaneous certolizumab pegol: an analysis of PRECiSE 2 randomized maintenance trial data","volume":"105","author":"Schreiber","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.crohns.2014.02.025_bb0065","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","article-title":"Infliximab, azathioprine, or combination therapy for Crohn's disease","volume":"362","author":"Colombel","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.crohns.2014.02.025_bb0070","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.gtc.2012.01.012","article-title":"Patient-specific approach to combination versus monotherapy with the use of antitumor necrosis factor alpha agents for inflammatory bowel disease","volume":"41","author":"Devlin","year":"2012","journal-title":"Gastroenterol Clin North Am"},{"key":"10.1016\/j.crohns.2014.02.025_bb0075","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1586\/egh.10.4","article-title":"What is the optimal therapy for Crohn's disease: step-up or top-down?","volume":"4","author":"Lin","year":"2010","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.crohns.2014.02.025_bb0080","first-page":"346","article-title":"Inflammatory bowel disease therapy: current state-of-the-art","volume":"27","author":"Blonski","year":"2011","journal-title":"Curr Opin Gastroenterol"},{"key":"10.1016\/j.crohns.2014.02.025_bb0085","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1053\/j.gastro.2008.10.051","article-title":"Infliximab prevents Crohn's disease recurrence after ileal resection","volume":"136","author":"Regueiro","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.crohns.2014.02.025_bb0090","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.cgh.2010.01.016","article-title":"Low-dose maintenance therapy with infliximab prevents postsurgical recurrence of Crohn's disease","volume":"8","author":"Sorrentino","year":"2010","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.crohns.2014.02.025_bb0095","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1002\/ibd.21831","article-title":"Therapeutic drug monitoring of biologics for inflammatory bowel disease","volume":"18","author":"Colombel","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.crohns.2014.02.025_bb0100","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1038\/ajg.2010.9","article-title":"Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease","volume":"105","author":"Afif","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.crohns.2014.02.025_bb0105","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1080\/00365520802699278","article-title":"Individual medicine in inflammatory bowel disease: monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies","volume":"44","author":"Bendtzen","year":"2009","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.crohns.2014.02.025_bb0110","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1056\/NEJMoa050516","article-title":"Infliximab for induction and maintenance therapy for ulcerative colitis","volume":"353","author":"Rutgeerts","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.crohns.2014.02.025_bb0115","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/S1542-3565(04)00238-1","article-title":"Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease","volume":"2","author":"Hanauer","year":"2004","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.crohns.2014.02.025_bb0120","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1097\/MCG.0b013e3181ebaef9","article-title":"Long-term durability of infliximab treatment in Crohn's disease and efficacy of dose \u201cescalation\u201d in patients losing response","volume":"45","author":"Chaparro","year":"2011","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.crohns.2014.02.025_bb0125","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1517\/14712598.2012.644271","article-title":"Anti-TNF trough levels and detection of antibodies to anti-TNF in inflammatory bowel disease: are they ready for everyday clinical use?","volume":"12","author":"Miheller","year":"2012","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.crohns.2014.02.025_bb0130","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1111\/apt.12283","article-title":"Letter: dry blood spots for anti-TNF treatment monitoring in IBD","volume":"37","author":"Vande Casteele","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.crohns.2014.02.025_bb0135","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S0016-5085(76)80163-1","article-title":"Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study","volume":"70","author":"Best","year":"1976","journal-title":"Gastroenterology"},{"key":"10.1016\/j.crohns.2014.02.025_bb0140","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S0140-6736(80)92767-1","article-title":"A simple index of Crohn's-disease activity","volume":"1","author":"Harvey","year":"1980","journal-title":"Lancet"},{"key":"10.1016\/j.crohns.2014.02.025_bb0145","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/S0016-5085(89)80080-0","article-title":"A new measure of health status for clinical trials in inflammatory bowel disease","volume":"96","author":"Guyatt","year":"1989","journal-title":"Gastroenterology"},{"key":"10.1016\/j.crohns.2014.02.025_bb0150","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1097\/00005176-199904001-00003","article-title":"Development and subsequent refinement of the inflammatory bowel disease questionnaire: a quality-of-life instrument for adult patients with inflammatory bowel disease","volume":"28","author":"Irvine","year":"1999","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.crohns.2014.02.025_bb0155","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1080\/gas.37.7.818.824","article-title":"A positive response to infliximab in Crohn disease: association with a higher systemic inflammation before treatment but not with \u2212308 TNF gene polymorphism","volume":"37","author":"Louis","year":"2002","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.crohns.2014.02.025_bb0160","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.cgh.2011.02.008","article-title":"Levels of C-reactive protein are associated with response to infliximab therapy in patients with Crohn's disease","volume":"9","author":"Jurgens","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.crohns.2014.02.025_bb0165","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1111\/j.1365-2036.2011.04827.x","article-title":"Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn's disease","volume":"34","author":"Kiss","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.crohns.2014.02.025_bb0170","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1080\/00365520410007971","article-title":"Normalization of faecal calprotectin: a predictor of mucosal healing in patients with inflammatory bowel disease","volume":"39","author":"Roseth","year":"2004","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.crohns.2014.02.025_bb0175","doi-asserted-by":"crossref","first-page":"325","DOI":"10.3109\/00365520903483650","article-title":"Faecal calprotectin and lactoferrin are reliable surrogate markers of endoscopic response during Crohn's disease treatment","volume":"45","author":"Sipponen","year":"2010","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.crohns.2014.02.025_bb0180","doi-asserted-by":"crossref","first-page":"538","DOI":"10.3109\/00365521.2012.667146","article-title":"Mucosal cytokine gene expression profiles as biomarkers of response to infliximab in ulcerative colitis","volume":"47","author":"Rismo","year":"2012","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.crohns.2014.02.025_bb0185","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1002\/ibd.21301","article-title":"Predictive value of epithelial gene expression profiles for response to infliximab in Crohn's disease","volume":"16","author":"Arijs","year":"2010","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.crohns.2014.02.025_bb0190","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1038\/ajg.2010.95","article-title":"Disease activity, ANCA, and IL23R genotype status determine early response to infliximab in patients with ulcerative colitis","volume":"105","author":"Jurgens","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.crohns.2014.02.025_bb0195","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1136\/gut.2009.178665","article-title":"Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis","volume":"58","author":"Arijs","year":"2009","journal-title":"Gut"},{"key":"10.1016\/j.crohns.2014.02.025_bb0200","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1056\/NEJMe1213371","article-title":"A glimpse of the next 100years in medicine","volume":"367","author":"Kohane","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.crohns.2014.02.025_bb0205","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1053\/j.gastro.2012.09.031","article-title":"Challenges to the design, execution, and analysis of randomized controlled trials for inflammatory bowel disease","volume":"143","author":"D'Haens","year":"2012","journal-title":"Gastroenterology"},{"issue":"Suppl. 2","key":"10.1016\/j.crohns.2014.02.025_bb0210","doi-asserted-by":"crossref","first-page":"S250","DOI":"10.1016\/S1873-9946(12)60505-4","article-title":"The future of inflammatory bowel disease management: combining progress in trial design with advances in targeted therapy","volume":"6","author":"Travis","year":"2012","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.crohns.2014.02.025_bb0215","series-title":"Expert Committee on Biological Standardization. Guidelines on Evaluation of Similar Biotherapeutic Products","author":"World Health Organization","year":"2009"},{"key":"10.1016\/j.crohns.2014.02.025_bb0220","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1517\/14712598.2012.758710","article-title":"Biosimilar monoclonal antibodies: a science-based regulatory challenge","volume":"13","author":"Declerck","year":"2013","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.crohns.2014.02.025_bb0225","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1093\/annonc\/mdm345","article-title":"The challenge of biosimilars","volume":"19","author":"Mellstedt","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.crohns.2014.02.025_bb0230","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1038\/nbt.1839","article-title":"Acceptable changes in quality attributes of glycosylated biopharmaceuticals","volume":"29","author":"Schiestl","year":"2011","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.crohns.2014.02.025_bb0235","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1136\/annrheumdis-2012-202715","article-title":"The role of biosimilars in the treatment of rheumatic diseases","volume":"72","author":"Dorner","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.crohns.2014.02.025_bb0240","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/nrrheum.2012.84","article-title":"The advent of biosimilar therapies in rheumatology\u2014\u201cO brave new world\u201d","volume":"8","author":"Scheinberg","year":"2012","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.crohns.2014.02.025_bb0245","series-title":"Committee for Medicinal Products for Human Use. Guideline on Similar Biological Medicinal Products Containing Monoclonal Antibodies \u2014 Non-clinical and Clinical Issues","author":"European Medicines Agency","year":"2012"},{"key":"10.1016\/j.crohns.2014.02.025_bb0250","series-title":"Guidance for Industry. Quality Considerations in Demonstrating Biosimilarity to a Reference Protein Product. Draft Guidance","author":"US Food and Drug Administration","year":"2012"},{"key":"10.1016\/j.crohns.2014.02.025_bb0255","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1038\/nbt.2447","article-title":"Setting the stage for biosimilar monoclonal antibodies","volume":"30","author":"Schneider","year":"2012","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.crohns.2014.02.025_bb0260","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1038\/nbt.2438","article-title":"Interchangeability, immunogenicity and biosimilars","volume":"30","author":"Ebbers","year":"2012","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.crohns.2014.02.025_bb0265","doi-asserted-by":"crossref","first-page":"561","DOI":"10.4155\/bio.13.6","article-title":"Assessing immunogenicity of biosimilar therapeutic monoclonal antibodies: regulatory and bioanalytical considerations","volume":"5","author":"Chamberlain","year":"2013","journal-title":"Bioanalysis"},{"key":"10.1016\/j.crohns.2014.02.025_bb0270","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1136\/annrheumdis-2012-203090","article-title":"A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study","volume":"72","author":"Yoo","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.crohns.2014.02.025_bb0275","first-page":"24","article-title":"Innovation and competition: will biosimilars succeed?: the creation of an FDA approval pathway for biosimilars is complex and fraught with hazard. Yes, innovation and market competition are at stake. But so are efficacy and patient safety","volume":"9","author":"Blackstone","year":"2012","journal-title":"Biotechnol Healthc"},{"key":"10.1016\/j.crohns.2014.02.025_bb0280","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1086\/510385","article-title":"The role of microbes in Crohn's disease","volume":"44","author":"Eckburg","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.crohns.2014.02.025_bb0285","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/j.0105-2896.2005.00291.x","article-title":"Experimental models of inflammatory bowel disease reveal innate, adaptive, and regulatory mechanisms of host dialogue with the microbiota","volume":"206","author":"Elson","year":"2005","journal-title":"Immunol Rev"},{"key":"10.1016\/j.crohns.2014.02.025_bb0290","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.chom.2008.05.001","article-title":"Metagenomic approaches for defining the pathogenesis of inflammatory bowel diseases","volume":"3","author":"Peterson","year":"2008","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.crohns.2014.02.025_bb0295","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1053\/j.gastro.2007.11.059","article-title":"Microbial influences in inflammatory bowel diseases","volume":"134","author":"Sartor","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.crohns.2014.02.025_bb0300","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1002\/ibd.20392","article-title":"Analysis of bacterial bowel communities of IBD patients: what has it revealed?","volume":"14","author":"Sokol","year":"2008","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.crohns.2014.02.025_bb0305","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1097\/MOG.0b013e328354586f","article-title":"Food and the gut microbiota in inflammatory bowel diseases: a critical connection","volume":"28","author":"Albenberg","year":"2012","journal-title":"Curr Opin Gastroenterol"},{"key":"10.1016\/j.crohns.2014.02.025_bb0310","doi-asserted-by":"crossref","first-page":"13780","DOI":"10.1073\/pnas.0706625104","article-title":"Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases","volume":"104","author":"Frank","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.crohns.2014.02.025_bb0315","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/ibd.21339","article-title":"Disease phenotype and genotype are associated with shifts in intestinal-associated microbiota in inflammatory bowel diseases","volume":"17","author":"Frank","year":"2011","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.crohns.2014.02.025_bb0320","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1053\/j.gastro.2011.11.032","article-title":"Rifaximin-extended intestinal release induces remission in patients with moderately active Crohn's disease","volume":"142","author":"Prantera","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.crohns.2014.02.025_bb0325","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1053\/gast.2000.9370","article-title":"Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial","volume":"119","author":"Gionchetti","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1016\/j.crohns.2014.02.025_bb0330","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1046\/j.1365-2036.1999.00560.x","article-title":"Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis","volume":"13","author":"Venturi","year":"1999","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.crohns.2014.02.025_bb0335","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1046\/j.1365-2036.2003.01465.x","article-title":"Effect of Lactobacillus rhamnosus GG on ileal pouch inflammation and microbial flora","volume":"17","author":"Kuisma","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.crohns.2014.02.025_bb0340","doi-asserted-by":"crossref","first-page":"16731","DOI":"10.1073\/pnas.0804812105","article-title":"Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients","volume":"105","author":"Sokol","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.crohns.2014.02.025_bb0345","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1126\/science.1198469","article-title":"Induction of colonic regulatory T cells by indigenous Clostridium species","volume":"331","author":"Atarashi","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.crohns.2014.02.025_bb0350","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/nature12331","article-title":"Treg induction by a rationally selected mixture of Clostridia strains from the human microbiota","volume":"500","author":"Atarashi","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.crohns.2014.02.025_bb0355","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1126\/science.1208344","article-title":"Linking long-term dietary patterns with gut microbial enterotypes","volume":"334","author":"Wu","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.crohns.2014.02.025_bb0360","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/nature11225","article-title":"Dietary-fat-induced taurocholic acid promotes pathobiont expansion and colitis in Il10\u2212\/\u2212 mice","volume":"487","author":"Devkota","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.crohns.2014.02.025_bb0365","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.gtc.2012.08.008","article-title":"Fecal microbiota transplantation: techniques, applications, and issues","volume":"41","author":"Borody","year":"2012","journal-title":"Gastroenterol Clin North Am"},{"key":"10.1016\/j.crohns.2014.02.025_bb0370","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/nrgastro.2011.244","article-title":"Fecal microbiota transplantation and emerging applications","volume":"9","author":"Borody","year":"2012","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.crohns.2014.02.025_bb0375","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1097\/MCG.0b013e3181c87e02","article-title":"Changes in the composition of the human fecal microbiome after bacteriotherapy for recurrent Clostridium difficile-associated diarrhea","volume":"44","author":"Khoruts","year":"2010","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.crohns.2014.02.025_bb0380","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1056\/NEJMoa1205037","article-title":"Duodenal infusion of donor feces for recurrent Clostridium difficile","volume":"368","author":"van Nood","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.crohns.2014.02.025_bb0385","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1111\/j.1365-2036.2012.05220.x","article-title":"Systematic review: faecal microbiota transplantation in the management of inflammatory bowel disease","volume":"36","author":"Anderson","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.crohns.2014.02.025_bb0390","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/nature11582","article-title":"Host\u2013microbe interactions have shaped the genetic architecture of inflammatory bowel disease","volume":"491","author":"Jostins","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.crohns.2014.02.025_bb0395","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1097\/MIB.0b013e318280b19e","article-title":"Combined serological, genetic, and inflammatory markers differentiate non-IBD, Crohn's disease, and ulcerative colitis patients","volume":"19","author":"Plevy","year":"2013","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.crohns.2014.02.025_bb0400","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1002\/ibd.21293","article-title":"Genetic predictors of medically refractory ulcerative colitis","volume":"16","author":"Haritunians","year":"2010","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.crohns.2014.02.025_bb0405","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/j.cgh.2009.05.001","article-title":"Genetic risk profiling and prediction of disease course in Crohn's disease patients","volume":"7","author":"Henckaerts","year":"2009","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.crohns.2014.02.025_bb0410","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1002\/ibd.21661","article-title":"Combination of genetic and quantitative serological immune markers are associated with complicated Crohn's disease behavior","volume":"17","author":"Lichtenstein","year":"2011","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.crohns.2014.02.025_bb0415","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1136\/gutjnl-2011-301957","article-title":"The NOD2insC polymorphism is associated with worse outcome following ileal pouch-anal anastomosis for ulcerative colitis","volume":"62","author":"Tyler","year":"2013","journal-title":"Gut"},{"key":"10.1016\/j.crohns.2014.02.025_bb0420","doi-asserted-by":"crossref","first-page":"e13085","DOI":"10.1371\/journal.pone.0013085","article-title":"Gene expression changes associated with resistance to intravenous corticosteroid therapy in children with severe ulcerative colitis","volume":"5","author":"Kabakchiev","year":"2010","journal-title":"PLoS One"}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S1873994614000944?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S1873994614000944?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/8\/8\/726\/1417297\/8-8-726.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T19:29:22Z","timestamp":1648841362000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-lookup\/doi\/10.1016\/j.crohns.2014.02.025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8]]},"references-count":84,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["S1873994614000944"],"URL":"https:\/\/doi.org\/10.1016\/j.crohns.2014.02.025","relation":{},"ISSN":["1873-9946"],"issn-type":[{"value":"1873-9946","type":"print"}],"subject":[],"published":{"date-parts":[[2014,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Future directions in inflammatory bowel disease management","name":"articletitle","label":"Article Title"},{"value":"Journal of Crohn's and Colitis","name":"journaltitle","label":"Journal Title"},{"value":"http:\/\/dx.doi.org\/10.1016\/j.crohns.2014.02.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 European Crohn's and Colitis Organisation. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}